Aptamer Group extends Unilever collaboration for deodorant Optimers

Aptamer Group

Aptamer Group plc (LON:APTA), the leading developer of next-generation synthetic binders delivering innovation to the life science industry, has announced that additional paid work has been commissioned by the global consumer goods company, Unilever, under the existing collaboration agreement between the two companies. The new work supports the ongoing development of Optimers as active ingredients for use in deodorant products.

Aptamer’s proprietary deodorant Optimers are precision-engineered to target and inhibit C-S Lyase, the key enzyme in skin bacteria responsible for generating body odour. Initial laboratory evaluations have demonstrated outstanding efficacy in preventing odour formation, with recent end-of-2024 testing confirming exceptional stability in skin samples over 72 hours – matching or exceeding the longevity performance of market-leading deodorants, with an anticipated clean safety profile.

Launched in 2022, this collaborative programme has now progressed to an expanded phase, supported by an additional undisclosed payment from Unilever. The enhanced scope includes comprehensive testing under diverse conditions, with a focus on advanced stability assessments to pave the way for imminent on-person functionality trials. This milestone underscores the growing confidence in Optimer technology’s potential to deliver superior, targeted solutions in personal care.

Unilever commands over 30 per cent. of the global deodorant market, compared to 10 per cent. for its nearest competitor. With the sector expected to grow at a CAGR of 4.5 per cent. over the next five years, the commercial opportunity for Aptamer in personal care is significant.

Dr Arron Tolley, Chief Executive Officer of Aptamer Group, said:

“We are thrilled with the continued momentum in our Unilever collaboration, which highlights the real-world potential of our Optimer platform. This latest paid extension for expanded stability testing is a critical advancement toward on-person trials and validates the superior performance we have achieved so far.

“Partnering with a powerhouse like Unilever not only accelerates our technology’s path to market but also opens doors to broader applications in personal care and beyond. We are optimistic about the value this creates for shareholders as we drive toward commercialisation to capture a share of this expansive market.”

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

    Aptamer Group secures £360,000 contract with top 3 global pharma

    Aptamer Group has signed a £360,000 development contract with a leading global pharmaceutical company to engineer Optimer® binders as targeted radiopharmaceuticals.

    Aptamer Group to present at ShareSoc Growth Company seminar in Leeds

    Aptamer will present at the ShareSoc Growth Company Seminar on Wednesday, 8 October 2025, at the Leonardo Hotel, Leeds. CEO Dr Arron Tolley and CFO Andrew Rapson will update investors on the Company’s progress, with a recording of the presentation to be published on the Aptamer website after the event.

    Aptamer signs contract with Metir for Cryptosporidium detection binders

    Aptamer has signed a new contract with Metir plc to develop Optimer® binders for the rapid detection of Cryptosporidium parvum oocysts in Metir’s Pathogen Detector platform.

    Aptamer signs therapeutic development deal with Invizius

    Aptamer Group has entered a new agreement with Invizius to develop Optimer® binders targeting the complement system for inflammatory and autoimmune diseases. The collaboration aims to enhance Invizius’ H-Guard® platform, currently in Phase 2 trials, by providing safer and more precise therapies, including potential treatments for IgA nephropathy.

    Aptamer advances enzyme modulation projects and expands pharma collaboration

    Aptamer Group announced progress on its Optimer® enzyme modulation projects, including a 10-year non-exclusive licensing deal forecast to cover around 15% of annual overheads and further agreements under discussion with global enzyme distributors.

    Aptamer secures contract Eetension with top 5 pharma partner

    Aptamer has extended its collaboration with a top 5 global pharmaceutical company to advance Optimer® binders into a fully functional ELISA assay. The agreement builds on the successful completion of the initial binder development phase, with Aptamer retaining IP ownership to support future commercialisation opportunities.

      Search

      Search